Grace Therapeutics Narrows Focus on GTx-104 After $13.5M IP Impairment
Event summary
- Grace Therapeutics recorded a $13.5M impairment of IPR&D for GTx-101 and GTx-102, refocusing on GTx-104.
- Secured $10M in private placement financing to support manufacturing and regulatory work for GTx-104.
- FDA’s CRL identified no clinical safety or efficacy deficiencies but required CMC and non-clinical data fixes.
- Dual-source manufacturing strategy initiated with two contract manufacturers to mitigate remediation risks.
The big picture
Grace Therapeutics is doubling down on GTx-104, its lead asset for aSAH patients, after deprioritizing two other candidates. The strategic shift comes as the company navigates FDA’s CRL, which demands fixes in manufacturing and non-clinical data but no additional clinical trials. With $22.2M in cash and a dual-source manufacturing strategy, Grace aims to mitigate risks while extending its runway through 2028.
What we're watching
- Regulatory Headwinds
- Whether Grace Therapeutics can successfully address FDA’s CRL items and resubmit NDA for GTx-104.
- Execution Risk
- The pace at which the dual-source manufacturing strategy progresses and which site reaches readiness first.
- Cash Runway
- How Grace Therapeutics manages its $22.2M in cash through 2028 amid ongoing regulatory and manufacturing costs.